# Thomas Ybert

> Thomas Ybert is the co-founder and Chief Scientific Officer of DNA Script, which develops enzymatic DNA synthesis technology and the SYNTAX benchtop DNA printer. His earlier research at Sanofi and on the Total-Amyris biofuel collaboration exposed the slow DNA supply cycles that motivated the company. He served as founding CEO from 2014 until October 2024.

- **Role:** Co-founder and Chief Scientific Officer at DNA Script
- **Organizations:** DNA Script, Sanofi, Total / TotalEnergies, Amyris
- **Education:** Engineering diploma, physics, École Polytechnique, Engineering diploma, molecular biology, AgroParisTech / Institut national agronomique Paris-Grignon, PhD in biotechnology; doctoral research at Sanofi, École Polytechnique doctoral school
- **Known for:** Co-founded DNA Script with Sylvain Gariel and Xavier Godron in 2014., Recognized by the Fondation Norbert Ségard with its 2016 young engineer entrepreneur prize., Led DNA Script as founding CEO through development and commercial launch of SYNTAX in June 2021.

## Career timeline

- **2007-2010** — Doctoral research in Sanofi R&D, working on a yeast-based production platform.
- **2010-2014** — Worked in Total’s New Energies division; helped establish and operate its bio-jet-fuel collaboration with Amyris, including two years in the San Francisco area.
- **2013** — Began allocating personal time to the DNA Script project with Sylvain Gariel and Xavier Godron.
- **2014** — Co-founded DNA Script and became its founding CEO.
- **2016** — Received the Fondation Norbert Ségard young engineer entrepreneur prize.
- **2019** — DNA Script reported a 200-nucleotide enzymatic synthesis milestone and announced its US office.
- **2021** — DNA Script commercially launched the SYNTAX System on June 15.
- **2024** — Moved to Chief Scientific Officer as Marc Montserrat became CEO on October 17.

## Achievements

- Co-founded DNA Script with Sylvain Gariel and Xavier Godron in 2014.
- Recognized by the Fondation Norbert Ségard with its 2016 young engineer entrepreneur prize.
- Led DNA Script as founding CEO through development and commercial launch of SYNTAX in June 2021.
- DNA Script’s October 2024 appointment announcement reported more than €265 million in equity financing, more than 150 patent applications, and more than €20 million of income from products and collaborations since inception; these are company figures, not personal wealth.

## Latest updates

- **2026-07** — Company context: DNA Script announced an agreement with Imperial Life Sciences to distribute SYNTAX in India; Ybert’s personal involvement was not specified.
- **2026-03** — Company context: distribution agreements expanded SYNTAX access in Latin America, Japan and South Korea.
- **2025-02** — Ybert discussed DNA printing, company building and US expansion in Flot.bio episode 27, published February 3.
- **2024-10** — DNA Script announced his move from founding CEO to Chief Scientific Officer; Ybert explained the transition in a public LinkedIn article the following day.

## Links

- Website: https://www.dnascript.com/
- LinkedIn: https://www.linkedin.com/in/thomasybert/

---

Profile page: https://yespress.io/thomas-ybert
Published by YesPress — https://yespress.io
Last updated: 2026-10-12